Vimseltinib
Romvimza (vimseltinib) is a small molecule pharmaceutical. Vimseltinib was first approved as Romvimza on 2025-02-14.
Download report
Favorite
Events Timeline
Commercial
Clinical
Drug
Target
Variants
Financial
Trends
Safety
Events Timeline
5D
1M
3M
6M
YTD
1Y
2Y
5Y
Max
Events
FDA approval date
EMA approval date
Patent expiration date
Study first post date
Last update post date
Start date
Primary completion date
Completion date
Results first post date
Mock data
Subscribe for the real data
Subscribe for the real data
Commercial
Therapeutic Areas
No data
Trade Name
FDA
EMA
Romvimza
Drug Products
FDA
EMA
New Drug Application (NDA)
New Drug Application (NDA)
Abbreviated New Drug Application (ANDA)
Abbreviated New Drug Application (ANDA)
Vimseltinib
Tradename | Company | Number | Date | Products |
|---|---|---|---|---|
| ROMVIMZA | Deciphera Pharmaceuticals | N-219304 RX | 2025-02-14 | 3 products, RLD, RS |
Labels
FDA
EMA
Brand Name | Status | Last Update |
|---|---|---|
| romvimza | New Drug Application | 2025-02-18 |
Indications
FDA
EMA
No data
Agency Specific
FDA
EMA
Expiration | Code | ||
|---|---|---|---|
VIMSELTINIB, ROMVIMZA, DECIPHERA PHARMS | |||
| 2030-02-14 | NCE | ||
ATC Codes
No data
HCPCS
No data
Clinical
Clinical Trials
4 clinical trials
View more details
Mock data
Subscribe for the real data
Subscribe for the real data
Indications Phases 4
No data
Indications Phases 3
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Neoplasms | D009369 | — | C80 | 1 | 1 | 1 | — | — | 2 |
| Synovitis | D013585 | EFO_0008997 | M67.5 | 1 | 1 | 1 | — | — | 2 |
| Giant cell tumors | D005870 | — | — | 1 | 1 | 1 | — | — | 2 |
| Pigmented villonodular synovitis | D013586 | EFO_1001106 | M12.2 | 1 | 1 | 1 | — | — | 2 |
| Giant cell tumor of tendon sheath | D000070779 | — | — | 1 | 1 | 1 | — | — | 2 |
Indications Phases 2
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Graft vs host disease | D006086 | — | D89.81 | — | 1 | — | — | — | 1 |
| Bronchiolitis obliterans syndrome | D000092122 | — | D89.811 | — | 1 | — | — | — | 1 |
Indications Phases 1
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Sarcoma | D012509 | — | — | 1 | — | — | — | — | 1 |
| Leiomyosarcoma | D007890 | — | — | 1 | — | — | — | — | 1 |
| Fibrosarcoma | D005354 | — | — | 1 | — | — | — | — | 1 |
| Liposarcoma | D008080 | — | — | 1 | — | — | — | — | 1 |
| Malignant fibrous histiocytoma | D051677 | — | — | 1 | — | — | — | — | 1 |
Indications Without Phase
No data
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
| Drug common name | Vimseltinib |
| INN | vimseltinib |
| Description | Vimseltinib, sold under the brand name Romvimza, is an anti-cancer medication used for the treatment of tenosynovial giant cell tumor. Vimseltinib is a kinase inhibitor. Vimseltinib is a macrophage colony-stimulating factor receptor antagonist.
|
| Classification | Small molecule |
| Drug class | tyrosine kinase inhibitors |
| Image (chem structure or protein) |  |
| Structure (InChI/SMILES or Protein Sequence) | Cc1nc(-c2cnc(NC(C)C)n(C)c2=O)ccc1Oc1ccnc(-c2cnn(C)c2)c1 |
Identifiers
| PDB | — |
| CAS-ID | 1628606-05-2 |
| RxCUI | — |
| ChEMBL ID | CHEMBL5095202 |
| ChEBI ID | — |
| PubChem CID | 86267612 |
| DrugBank | DB17520 |
| UNII ID | PX9FTM69BF (ChemIDplus, GSRS) |
Target
No data
Variants
No data
Financial
No data
Trends
No data
Safety
Black-box Warning
No Black-box warning
Adverse Events
© 2020-2025 Collaborative Drug Discovery Inc. (CDD) | Terms of Use